Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydroxychloroquine and Azithromycin in Moderate to Severe COVID-19
NCT04329572Phase 1Suspended
- Sponsor
- Azidus Laboratories Limited
- Start
- Apr 2020
- Primary completion
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of hydroxychloroquine and azithromycin in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Azidus Laboratories Limited. Primary endpoint: Evolution of acute respiratory syndrome, oxygen saturation hemodynamic stability at 28 days. Started Apr 2020; status: suspended.
02
Drugs
hydroxychloroquineazithromycin
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04329572.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04329572.